Table 3.
HR-HPV viral load at enrollment and association with persistent infection over two years stratified by trial arm.
Intervention |
Control |
Overall |
||||
---|---|---|---|---|---|---|
High Viral Load^ |
Low Viral Load^ |
High Viral Load^ |
Low Viral Load^ |
High Viral Load^ |
Low Viral Load^ |
|
Persistent HR-HPV / N* (%) | Persistent HR-HPV / N* (%) | Persistent HR-HPV / N* (%) | Persistent HR-HPV / N* (%) | Persistent HR-HPV / N* (%) | Persistent HR-HPV / N* (%) | |
Year One | 89/207 (43.0%) | 35/145 (24.1%) | 83/210 (39.5%) | 36/128 (28.1%) | 172/417 (41.2%) | 71/273 (26.0%) |
Year Two | 27/89 (30.3%) | 16/35 (45.7%) | 48/83 (57.8%) | 17/36 (47.2%) | 75/172 (43.6%) | 33/71 (46.5%) |
Hazard Ratio | 1.07 (0.92 - 1.24) | 1.24 (1.06 - 1.46) | 1.15 (1.03 - 1.28) | |||
adjHR# | 1.24 (0.99 - 1.55) | 1.25 (0.98 - 1.60) | 1.27 (1.07 - 1.50) |
High HR-HPV viral load includes a linear array band signal strength of 3 or 4 which represents >200 copies/5μl. Low HR-HPV viral load comprises a linear array band signal strength of 1 or 2.
N is the number of total genotypes detected at enrollment classified as either high VL or low VL.
adjHR is an adjusted Hazard Ratio. The Hazard multivariate analysis adjusted for age in all models and circumcision status of male partner for the overall model.